BioCentury
ARTICLE | Clinical News

Rhizen, TG Therapeutics preclinical data

January 21, 2013 8:00 AM UTC

In antigen recognition studies using the Human Whole Blood B cell depletion assay, 1 uM TGR-1202 in combination 0.1-1 ng/mL ublituximab increased CD20-positive lymphoma cell depletion by 20% compared to TGR-1202 alone, which was not cytotoxic at the 1 uM concentration as monotherapy. Data were presented at the American Society of Hematology meeting in Atlanta. Last August, Rhizen partnered with TG Therapeutics to develop Rhizen's TGR-1202 for hematologic cancers and autoimmune diseases (see BioCentury, Aug. 20, 2012). TGR-1202, a phosphoinositide 3-kinase (PI3K) delta inhibitor, is in Phase I testing to treat relapsed or refractory hematologic malignancies. ...